Report cover image

Hedgehog Pathway Inhibitors Market by Generic Drug Name (Glasdegib, Sonidegib, Vismodegib), Dosage (Capsule, Injection), Distribution Channel, Cancer Indication, End-Users - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 197 Pages
SKU # IRE18444330

Description

Hedgehog Pathway Inhibitors Market by Generic Drug Name (Glasdegib, Sonidegib, Vismodegib), Dosage (Capsule, Injection), Distribution Channel, Cancer Indication, End-Users - Global Forecast 2024-2030


The Hedgehog Pathway Inhibitors Market size was estimated at USD 1.32 billion in 2023 and expected to reach USD 1.52 billion in 2024, at a CAGR 16.63% to reach USD 3.89 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hedgehog Pathway Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hedgehog Pathway Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hedgehog Pathway Inhibitors Market, highlighting leading vendors and their innovative profiles. These include BridgeBio Inc., Eli Lilly and Company, F. Hoffmann La Roche Ltd., Impact Therapeutics Inc., Kintor Pharmaceutical Limited, Max Biopharma Inc., Merck KGaA, Novartis AG, Pellepharm, Inc., Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage



This research report categorizes the Hedgehog Pathway Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

Generic Drug Name
Glasdegib
Sonidegib
Vismodegib
Dosage
Capsule
Injection
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Cancer Indication
Blood
Brain
Breast
Lung
Pancreas
Prostate
Skin
End-Users
Homecare
Hospitals
Specialty Clinics
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hedgehog Pathway Inhibitors Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hedgehog Pathway Inhibitors Market?
3. What are the technology trends and regulatory frameworks in the Hedgehog Pathway Inhibitors Market?
4. What is the market share of the leading vendors in the Hedgehog Pathway Inhibitors Market?
5. Which modes and strategic moves are suitable for entering the Hedgehog Pathway Inhibitors Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

197 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hedgehog Pathway Inhibitors Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of programs to create awareness about AML and BCC
5.1.1.2. Growing demand of minimally invasive surgeries
5.1.1.3. Significant prevalence of cancer across the globe
5.1.2. Restraints
5.1.2.1. Lack of adoption due to primary resistance
5.1.3. Opportunities
5.1.3.1. Rise in approvals for hedgehog pathway inhibitors
5.1.3.2. Ongoing research and development activities
5.1.4. Challenges
5.1.4.1. Concern regarding efficacy and safety issues
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Hedgehog Pathway Inhibitors Market, by Generic Drug Name
6.1. Introduction
6.2. Glasdegib
6.3. Sonidegib
6.4. Vismodegib
7. Hedgehog Pathway Inhibitors Market, by Dosage
7.1. Introduction
7.2. Capsule
7.3. Injection
8. Hedgehog Pathway Inhibitors Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Hedgehog Pathway Inhibitors Market, by Cancer Indication
9.1. Introduction
9.2. Blood
9.3. Brain
9.4. Breast
9.5. Lung
9.6. Pancreas
9.7. Prostate
9.8. Skin
10. Hedgehog Pathway Inhibitors Market, by End-Users
10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Hedgehog Pathway Inhibitors Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Hedgehog Pathway Inhibitors Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Hedgehog Pathway Inhibitors Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. BridgeBio Inc.
15.1.2. Eli Lilly and Company
15.1.3. F. Hoffmann La Roche Ltd.
15.1.4. Impact Therapeutics Inc.
15.1.5. Kintor Pharmaceutical Limited
15.1.6. Max Biopharma Inc.
15.1.7. Merck KGaA
15.1.8. Novartis AG
15.1.9. Pellepharm, Inc.
15.1.10. Pfizer Inc.
15.1.11. Sanofi S.A.
15.1.12. Sun Pharmaceutical Industries Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. HEDGEHOG PATHWAY INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, 2023 VS 2030
FIGURE 3. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HEDGEHOG PATHWAY INHIBITORS MARKET DYNAMICS
FIGURE 7. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2023 VS 2030 (%)
FIGURE 8. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY GENERIC DRUG NAME, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
FIGURE 10. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2023 VS 2030 (%)
FIGURE 14. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY CANCER INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 16. HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HEDGEHOG PATHWAY INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. HEDGEHOG PATHWAY INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. HEDGEHOG PATHWAY INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us